CarolynYMullerMD
Obstetrics & Gynecology • Albuquerque, NMGynecologic Oncology
Professor, Obstetrics & Gynecology, University of New Mexico School of Medicine
Dr. Muller is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1201 Camino de Salud NE
Albuquerque, NM 87102Phone+1 505-272-0572- Is this information wrong?
Education & Training
University of Texas Southwestern Medical CenterFellowship, Gynecologic Oncology, 1993 - 1996
Pennsylvania Hospital of the University of Pennsylvania Health SystemResidency, Obstetrics and Gynecology, 1988 - 1992
Perelman School of Medicine at the University of PennsylvaniaClass of 1988
Certifications & Licensure
NJ State Medical License 1992 - Present
TX State Medical License 1994 - 2025
NM State Medical License 2004 - 2025
PA State Medical License 1991 - 1998- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2014
- Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Clinical Trials
- Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal Cancer Start of enrollment: 1998 Sep 01
- Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Start of enrollment: 2005 Mar 21
- Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
- Join now to see all
Publications & Presentations
PubMed
- Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016.Lilian T Gien, Danielle M Enserro, Linda R Duska, Andrea E Wahner-Hendrickson, Premal H Thaker, Allan Covens, Kathleen N Moore, Robert L Coleman, Matthew S Block, Stev...> ;Gynecologic Oncology. 2024 Apr 10
- 8 citationsEffects of the WRITE Symptoms Interventions on Symptoms and Quality of Life Among Patients With Recurrent Ovarian Cancers: An NRG Oncology/GOG Study (GOG-0259).Heidi S Donovan, Susan M Sereika, Lari B Wenzel, Robert P Edwards, Judith E Knapp, Susan H Hughes, Mary C Roberge, Teresa H Thomas, Sara Jo Klein, Michael B Spring, Su...> ;Journal of Clinical Oncology. 2022 May 1
- 35 citationsOlaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III T...Joyce F Liu, Mark F Brady, Ursula A Matulonis, Austin Miller, Elise C Kohn, Elizabeth M Swisher, David Cella, William P Tew, Noelle G Cloven, Carolyn Y Muller, David P...> ;Journal of Clinical Oncology. 2022 Jul 1
- Join now to see all
Press Mentions
Online Tool Helps Ovarian Cancer Patients Feel More in Control of SymptomsFebruary 7th, 2022- Cheryl Willman Named Head of Mayo Clinic Cancer Programs, Director of Cancer CenterMay 17th, 2021
- Dr. Cheryl Willman Named Executive Director, Mayo Clinic Cancer Programs; Director, Mayo Clinic Comprehensive Cancer CenterMay 17th, 2021
- Join now to see all
Professional Memberships
- Fellow
Hospital Affiliations
- Lovelace Medical CenterAlbuquerque, New Mexico
University of New Mexico HospitalsAlbuquerque, New Mexico
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
